(INSM) Insmed - Ratings and Ratios
Liposomal Antibiotic, DPP1 Inhibitor, Treprostinil Inhalation, Gene Therapy
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 44.8% |
| Value at Risk 5%th | 64.4% |
| Relative Tail Risk | -12.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.97 |
| Alpha | 136.82 |
| CAGR/Max DD | 3.77 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.544 |
| Beta | 0.597 |
| Beta Downside | 0.839 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.69% |
| Mean DD | 7.90% |
| Median DD | 7.15% |
Description: INSM Insmed December 17, 2025
Insmed Inc. (NASDAQ: INSM) focuses on developing and commercializing therapies for rare, serious respiratory diseases. Its only currently marketed product, ARIKAYCE (liposomal amikacin), is approved for refractory nontuberculous mycobacterial (NTM) lung infections, and the company is pursuing a Phase 3 trial of a combination regimen for Mycobacterium avium complex (MAC) disease. The pipeline also includes brensocatib (a reversible DPP-1 inhibitor) in Phase 3 for bronchiectasis and Phase 2 for chronic rhinosinusitis without polyps and hidradenitis suppurativa, as well as treprostinil palmitil inhalation powder in Phase 3 for pulmonary hypertension associated with interstitial lung disease and Phase 2 for pulmonary arterial hypertension. Early-stage programs span a micro-dystrophin AAV gene therapy for Duchenne muscular dystrophy and next-generation DPP-1 inhibitors.
In FY 2023, ARIKAYCE generated approximately $140 million in revenue, representing a 25 % year-over-year increase, while the company posted a net loss of $210 million, largely driven by R&D spend that now exceeds $300 million annually. Cash and cash equivalents of $340 million give Insmed a runway of roughly 12-18 months under current burn rates, assuming no material trial failures or unexpected regulatory setbacks. The NTM market is estimated at $2-3 billion globally, growing at 6-8 % CAGR, providing a modest but defensible niche for ARIKAYCE and potential upside from MAC approvals.
The biotech sector’s valuation is heavily influenced by the success rate of Phase 3 trials (historically ~55 % for respiratory indications) and the pace of FDA review, both of which add considerable uncertainty to Insmed’s near-term outlook. A key driver will be whether brensocatib can achieve a differentiated efficacy signal in bronchiectasis, a disease affecting an estimated 600,000 U.S. patients and projected to expand with aging demographics. For a deeper quantitative assessment, you may find the ValueRay platform’s detailed valuation model for INSM worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-1.18b TTM) > 0 and > 6% of Revenue (6% = 26.8m TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -7.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 338.8% (prev 405.5%; Δ -66.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.37 (>3.0%) and CFO -883.4m > Net Income -1.18b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (211.4m) change vs 12m ago 21.71% (target <= -2.0% for YES) |
| Gross Margin 69.97% (prev 77.25%; Δ -7.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 20.26% (prev 16.71%; Δ 3.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -12.98 (EBITDA TTM -1.09b / Interest Expense TTM 84.7m) >= 6 (WARN >= 3) |
Altman Z'' -10.41
| (A) 0.64 = (Total Current Assets 1.93b - Total Current Liabilities 417.2m) / Total Assets 2.36b |
| (B) -2.25 = Retained Earnings (Balance) -5.31b / Total Assets 2.36b |
| warn (B) unusual magnitude: -2.25 — check mapping/units |
| (C) -0.50 = EBIT TTM -1.10b / Avg Total Assets 2.21b |
| (D) -3.75 = Book Value of Equity -5.30b / Total Liabilities 1.42b |
| Total Rating: -10.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.84
| 1. Piotroski 0.50pt |
| 2. FCF Yield -2.46% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.79 |
| 5. Debt/Ebitda -0.38 |
| 6. ROIC - WACC (= -83.35)% |
| 7. RoE -183.6% |
| 8. Rev. Trend 94.79% |
| 9. EPS Trend -4.78% |
What is the price of INSM shares?
Over the past week, the price has changed by +0.56%, over one month by -10.93%, over three months by +10.61% and over the past year by +162.79%.
Is INSM a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the INSM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 214.9 | 22.8% |
| Analysts Target Price | 214.9 | 22.8% |
| ValueRay Target Price | 230.7 | 31.8% |
INSM Fundamental Data Overview January 03, 2026
P/S = 84.5037
P/B = 39.2547
Beta = 1.017
Revenue TTM = 447.0m USD
EBIT TTM = -1.10b USD
EBITDA TTM = -1.09b USD
Long Term Debt = 539.7m USD (from longTermDebt, last quarter)
Short Term Debt = 12.3m USD (from shortTermDebt, last quarter)
Debt = 745.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 410.3m USD (from netDebt column, last quarter)
Enterprise Value = 36.84b USD (37.77b + Debt 745.1m - CCE 1.68b)
Interest Coverage Ratio = -12.98 (Ebit TTM -1.10b / Interest Expense TTM 84.7m)
FCF Yield = -2.46% (FCF TTM -906.1m / Enterprise Value 36.84b)
FCF Margin = -202.7% (FCF TTM -906.1m / Revenue TTM 447.0m)
Net Margin = -264.8% (Net Income TTM -1.18b / Revenue TTM 447.0m)
Gross Margin = 69.97% ((Revenue TTM 447.0m - Cost of Revenue TTM 134.2m) / Revenue TTM)
Gross Margin QoQ = 58.74% (prev 73.86%)
Tobins Q-Ratio = 15.61 (Enterprise Value 36.84b / Total Assets 2.36b)
Interest Expense / Debt = 2.74% (Interest Expense 20.4m / Debt 745.1m)
Taxrate = -0.36% (negative due to tax credits) (1.32m / -368.7m)
NOPAT = -1.10b (EBIT -1.10b * (1 - -0.36%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.63 (Total Current Assets 1.93b / Total Current Liabilities 417.2m)
Debt / Equity = 0.79 (Debt 745.1m / totalStockholderEquity, last quarter 945.6m)
Debt / EBITDA = -0.38 (negative EBITDA) (Net Debt 410.3m / EBITDA -1.09b)
Debt / FCF = -0.45 (negative FCF - burning cash) (Net Debt 410.3m / FCF TTM -906.1m)
Total Stockholder Equity = 645.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.15% (Net Income -1.18b / Total Assets 2.36b)
RoE = -183.6% (Net Income TTM -1.18b / Total Stockholder Equity 645.0m)
RoCE = -92.82% (EBIT -1.10b / Capital Employed (Equity 645.0m + L.T.Debt 539.7m))
RoIC = -75.24% (negative operating profit) (NOPAT -1.10b / Invested Capital 1.47b)
WACC = 8.10% (E(37.77b)/V(38.52b) * Re(8.21%) + D(745.1m)/V(38.52b) * Rd(2.74%) * (1-Tc(-0.00)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.84%
Fair Price DCF = unknown (Cash Flow -906.1m)
EPS Correlation: -4.78 | EPS CAGR: 13.97% | SUE: 4.0 | # QB: 1
Revenue Correlation: 94.79 | Revenue CAGR: 28.17% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-1.18 | Chg30d=+0.146 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=-3.51 | Chg30d=+0.153 | Revisions Net=+2 | Growth EPS=+42.5% | Growth Revenue=+135.8%
Additional Sources for INSM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle